Macrocyclic Ras Inhibitors via Cyclophilin A Tri-Complex Occlusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug discovery efforts have been largely unsuccessful in targeting Ras proteins, which are undruggable targets and play a crucial role in various human cancers, despite their association with approximately 30% of all human cancers in the United States.
Innovation Solution
Formation of a high-affinity three-component complex between a synthetic ligand and two intracellular proteins, Ras and cyclophilin A, creating a new binding pocket that sterically occludes the interaction site between Ras and downstream effector molecules, thereby inhibiting oncogenic signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule drugs are used to target Ras proteins, then the drug can bind to a functionally important pocket on the target protein, but Ras proteins are undruggable and lack accessible binding pockets for small molecules
Solution Approach 1:
The patent introduces cyclophilin A as an intermediary protein that bridges the small molecule drug and the Ras target. The tri-complex structure allows the drug to bind to cyclophilin A, which in turn binds to Ras, effectively mediating the interaction between a druggable component and an undruggable target. This resolves the contradiction by providing a functional binding pathway without requiring direct druggability of Ras itself.
Solution Approach 2:
The patent creates a composite molecular system consisting of three components: the small molecule drug, cyclophilin A, and Ras protein. This tri-complex composite structure combines the druggable properties of small molecules with the target specificity of Ras, achieving effective targeting through composite assembly rather than relying on a single small molecule-Ras interaction.
2Productivity
If extensive drug discovery efforts are directed at Ras proteins using conventional approaches, then more compounds can be screened, but no direct Ras-targeting drug has been approved despite decades of effort
Solution Approach 1:
Instead of attempting to directly bind small molecules to Ras (the conventional approach that has failed), the patent inverts the strategy by having small molecules bind to cyclophilin A, which then binds to Ras. This inverted binding pathway achieves Ras inhibition through an alternative route, transforming a failed direct-approach problem into a successful indirect-approach solution.
Solution Approach 2:
The patent uses cyclophilin A as a mediator protein to translate conventional small molecule drug discovery efforts into effective Ras targeting. By screening drugs against cyclophilin A (a druggable target) rather than Ras directly, the approach maintains high productivity in compound screening while achieving reliable therapeutic results through the mediating tri-complex mechanism.
3Reliability
If a tri-complex structure is formed between synthetic ligand and two intracellular proteins, then a new binding pocket is created that sterically occludes effector interaction, but the system complexity increases with multiple protein-ligand interactions
Solution Approach 1:
The patent assigns multiple functions to cyclophilin A within the tri-complex: it serves as a drug binding platform, a Ras binding partner, and a structural organizer that creates the inhibitory geometry. This multi-functionality reduces overall system complexity by consolidating multiple roles into a single intermediary protein rather than requiring separate components for each function.
Solution Approach 2:
The tri-complex structure exhibits a nested arrangement where the small molecule drug is bound within cyclophilin A, which in turn is bound to Ras. This nested configuration achieves efficient spatial organization and steric occlusion of effector binding sites while maintaining a compact, manageable complex structure rather than a dispersed multi-component system.
Data Source
AI summary
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.